5th International Molecular Immunology & Immunogenetics Congress, İzmir, Turkey, 20 - 22 October 2022, pp.124
Introduction: Tumor-Associated Antigens (TAAs) are protein and glycoprotein-based substances that are derived from tumor cells. They are over-expressed in cancer cells compared to normal cells and also abundantly presented on the surface of cancer cells. Peptides of these TAAs bound to human leukocyte antigen (HLA) can be recognized by T cells initiating an anti-cancer immune response. Melanoma is one of the most aggressive cancers arising from the malignant transformation of melanocytes located in the basal layer of the epidermis. Skin cancers emerge as a serious public health problem in countries such as Turkey, which are exposed to intense sunlight during certain year seasons. In recent years, immunotherapies with cancer-specific adoptive cell transfer (ACT) have targeted intracellular tumor-associated antigens. In this study, we demonstrated the expression of TAAs identified previously in the literature in different stages and subgroups of cutaneous melanoma. Methods: Immunohistochemical staining of tumor tissues of melanoma patients (n= 34) was performed on Ventana Benchmark XT automated instrument. Deparaffinization of embedded tissues was performed by keeping them at 50 C during the night. All tumor tissues were labeled with melanoma-associated markers such as TRP-1, TRP-2, NY-ESO-1, MAGE-A, MAGE-C1, Tyrosinase, HMB45, and MART-1. The expressions of these markers were determined by Alkaline Phosphatase Red Detection under the microscope. Result: According to our results we observed that TRP-2 showed the highest expression in acral lentiginous, lentigo maligna, and nodular malignant melanomas while superficial spreading malignant melanoma had increased Tyrosinase expression. In addition to differential antigen expressions of melanoma-associated markers were also changed depending on the stages of the disease.
This study is being supported by The Scientific and Technological Research Council of Türkiye (TUBITAK), Project no: 218S910